Biology of Blood and Marrow Transplantation最新文献

{"title":"Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease","authors":"Debra Lynch Kelly ,&nbsp;Nosha Farhadfar ,&nbsp;Angela Starkweather ,&nbsp;Timothy J Garrett ,&nbsp;Yingwei Yao ,&nbsp;John R. Wingard ,&nbsp;Iqbal Mahmud ,&nbsp;Victoria Menzies ,&nbsp;Param Patel ,&nbsp;Karima M. Alabasi ,&nbsp;Debra Lyon","doi":"10.1016/j.bbmt.2020.06.014","DOIUrl":"10.1016/j.bbmt.2020.06.014","url":null,"abstract":"<div><p>Chronic graft-versus-host disease (cGVHD) remains a significant late effect issue for allogeneic hematopoietic cell transplantation (allo-HCT) survivors, contributing to morbidity and mortality. The etiology of cGVHD is not well elucidated. Owing to a lack of early diagnostic tests and pathophysiology ambiguity, targeted treatments remain limited. Biomarkers for prediction, control response, or prognostication have not yet been identified. Metabolomics, the quantification of metabolites, is a potential biomarker of cGVHD but has not been evaluated in this population. In this study, we examined global metabolites of stored plasma to identify differentially expressed metabolites of individuals discordant for cGVHD following allo-HCT. A descriptive, comparative, cross-sectional study design was used to examine differentially expressed metabolites of plasma samples obtained from 40 adult allo-HCT recipients (20 with cGVHD and 20 without cGVHD) from 2 parent studies. Metabolomics profiling was conducted at the University of Florida's Southeast Center for Integrative Metabolomics. Full experimental methods followed a previously published method. All statistical analyses were performed by a PhD-prepared, trained bioinformatics statistician. There were 10 differentially expressed metabolites between participants with cGVHD and those without cGVHD. Differential metabolites included those related to energy metabolism (n = 3), amino acid metabolism (n = 3), lipid metabolism (n = 2), caffeine metabolism (n = 1), and neurotransmission (n = 1). Serotonin had the greatest fold change (21.01). This study suggests that cGVHD may be associated with expanded cellular energy and potentially mitochondrial dysfunction. The differential metabolic profile between patients with and without cGVHD indicates metabolic perturbations that merit further exploration as potential biomarkers of cGVHD. These findings support the need for further examination using a larger, prospective study design to identify metabolomic risk factors that may signal the need for earlier preventive measures and earlier treatment to reduce cGVHD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1803-1810"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38092965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenomegaly May Increase the Risk of Rejection in Low-Risk Matched Related Donor Transplant for Thalassemia, This Risk Can Be Partially Overcome by Additional Immunosuppression during Conditioning","authors":"Stalin Ramprakash ,&nbsp;C.P. Raghuram ,&nbsp;Priya Marwah ,&nbsp;Rajpreet Soni ,&nbsp;Deepa Trivedi ,&nbsp;Sadaf Khalid ,&nbsp;Naila Yaqub ,&nbsp;Fatima Itrat ,&nbsp;Sarah Khan Gilani ,&nbsp;Tatheer Zahra ,&nbsp;Rakesh Dhanya ,&nbsp;Rajat Kumar Agarwal ,&nbsp;Lawrence Faulkner","doi":"10.1016/j.bbmt.2020.06.013","DOIUrl":"10.1016/j.bbmt.2020.06.013","url":null,"abstract":"<div><p>Severe thalassemia syndromes (ST) are highly curable by bone marrow transplant (BMT), but rejection may still occur. We retrospectively analyzed our fully matched related donor transplants to establish if isolated splenomegaly is an independent risk factor for rejection and if this risk can be reduced by modifying the conditioning protocol. In this study, we compared rejection rates between patients with and without splenomegaly in 189 consecutive low-risk ST transplants across 2 sequential conditioning regimens: regimen A (August 2013 to December 2016): busulfan (14 mg/kg oral, not adjusted to serum levels), cyclophosphamide (200 mg/kg), and anti-thymocyte globulin (ATG) (Genzyme (Sanofi, Paris, France) 4 mg/kg or Fresenius (Grafalon, Neovii Biotech GmbH, Gräfelfing Germany) 16 mg/kg on days –12 to –10), and regimen B: same backbone as regimen A except fludarabine total dose of 150 mg was added upfront and ATG dose was increased to 7 mg/kg in case of splenomegaly and/or sex-mismatched transplants (January 2017 to September 2018). Compared with regimen A, in regimen B, both overall rejection rates (RRs) (16% versus 6.5%, <em>P = .</em>023) and treatment-related mortality (TRM) (9.9% versus 2.8%, <em>P</em> = .038) improved significantly. By Cox regression analysis, the improvement in RR between the 2 protocols was particularly significant in patients with splenomegaly (RR 54.5% versus 6.5%, <em>P = .</em>00015; TRM 18.2% versus 6.5%, <em>P = .</em>25) (hazard ratio, 4.13; confidence interval, 1.61 to 10.6; <em>P = .</em>003). The increased risk of rejection related to splenomegaly can be overcome by adding fludarabine to the standard ATG-Busulfan- Cyclophosphamide (ATG-Bu-Cy) protocol without significantly increasing transplant-related morbidity and mortality or resorting to splenectomy pre-BMT.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1886-1893"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38092963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?","authors":"Uri Greenbaum ,&nbsp;Fevzi F. Yalniz ,&nbsp;Samer A. Srour ,&nbsp;Katayoun Rezvani ,&nbsp;Harjeet Singh ,&nbsp;Amanda Olson ,&nbsp;George Blumenschein Jr ,&nbsp;David S. Hong ,&nbsp;Elizabeth J. Shpall ,&nbsp;Partow Kebriaei","doi":"10.1016/j.bbmt.2020.06.020","DOIUrl":"10.1016/j.bbmt.2020.06.020","url":null,"abstract":"<div><p>Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19⁺ B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including (1) on-target off-tumor toxicity, (2) optimal target identification, (3) effective trafficking into bulky tumor tissue, and (4) resistance to tumor immune evasion mechanisms.</p><p>Novel techniques and modifications are being explored in both the preclinical and clinical settings, aiming to improve treatment efficacy and address the aforementioned obstacles to successful CAR T therapy in solid tumors. Here we review these challenges in a clinically oriented approach and summarize published clinical trials using CAR T therapy in a variety of solid tumors.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1759-1769"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38123521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume of Gadolinium Enhancement and Successful Repair of the Blood-Brain Barrier in Cerebral Adrenoleukodystrophy","authors":"Troy C. Lund ,&nbsp;Michelle Ng ,&nbsp;Paul J. Orchard ,&nbsp;Daniel J. Loes ,&nbsp;Gerald V. Raymond ,&nbsp;Ashish Gupta ,&nbsp;Dan Kenny-Jung ,&nbsp;David R. Nascene","doi":"10.1016/j.bbmt.2020.06.019","DOIUrl":"10.1016/j.bbmt.2020.06.019","url":null,"abstract":"<div><p>Up to 40% of boys with adrenoleukodystrophy develop a severe central nervous system demyelinating form (cALD) characterized by white matter changes and gadolinium enhancement on magnetic resonance imaging (MRI). Hematopoietic cell transplant (HCT) is the only proven means to attenuate cALD progression. The elimination of active neuroinflammation is indicated radiographically by the resolution of gadolinium (Gd) enhancement and correlates to speed of donor neutrophil recovery. We analyzed 66 boys with cALD undergoing HCT for biomarkers correlating with early (30 days post-HCT) Gd signal resolution. We found that log Gd volume (cm³) on pre-HCT MRI strongly positively correlated to day 30 Gd resolution (<em>P</em> = .0003) with smaller volume correlating to higher proportion resolved, as was the baseline gadolinium intensity score (<em>P</em> = .04), plasma chitotriosidase activity (<em>P</em> = .04), and faster absolute neutrophil count recovery (<em>P</em> = .03). In multivariate analysis, log Gd volume remained superior in determining which patients would have Gd signal resolution by 30 days post-HCT (<em>P</em> = .016). A final analysis indicated that early Gd resolution also correlated with less neurologic progression from baseline to 1 year following HCT (<em>P</em> = .006). MRI Gd volume may serve as a contributing biomarker to better delineate outcomes and an important metric in comparing therapies in the treatment of cALD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1894-1899"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38098459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes","authors":"Dolores Grosso ,&nbsp;Matthew Carabasi ,&nbsp;Joanne Filicko-O'Hara ,&nbsp;John L. Wagner ,&nbsp;William O'Hara ,&nbsp;Michael Sun ,&nbsp;Beth Colombe ,&nbsp;W. Shi ,&nbsp;Maria Werner-Wasik ,&nbsp;Shannon Rudolph ,&nbsp;Onder Alpdogan ,&nbsp;Adam Binder ,&nbsp;Margaret Kasner ,&nbsp;Thomas Klumpp ,&nbsp;Ubaldo Martinez-Outschoorn ,&nbsp;Neil Palmisiano ,&nbsp;Lindsay Wilde ,&nbsp;Pierluigi Porcu ,&nbsp;Usama Gergis ,&nbsp;Neal Flomenberg","doi":"10.1016/j.bbmt.2020.06.021","DOIUrl":"10.1016/j.bbmt.2020.06.021","url":null,"abstract":"<div><p>The use of cyclophosphamide (CY) for bidirectional tolerization of recipient and donor T cells is associated with reduced rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after HLA-matched hematopoietic stem cell transplantation (HSCT). However, recurrent disease remains the primary barrier to long-term survival. We extended our 2-step approach to HLA-matched related HSCT using a radiation-based myeloablative conditioning regimen combined with a high dose of T cells in an attempt to reduce relapse rates while maintaining the beneficial effects of CY tolerization. After conditioning, patients received their grafts in 2 components: (1) a fixed dose of 2 × 10⁸/kg T cells, followed 2 days later by CY, and (2) a CD34-selected graft containing a small residual amount of non-CY-exposed T cells, at a median dose of 2.98 × 10³/kg. Forty-six patients with hematologic malignancies were treated. Despite the myeloablative conditioning regimen and use of high T cell doses, the cumulative incidences of grade II-IV acute GVHD, chronic GVHD, and NRM at 1 year and 5 years were very low, at 13%, 9%, and 4.3%, respectively. This contributed to a high overall survival of 89.1% at 1 year and 65.8% at 5 years. Relapse was the primary cause of mortality, with a cumulative incidence of 23.9% at 1 year and 45.7% at 5 years. In a post hoc analysis, relapse rates were significantly lower in patients receiving greater than versus those receiving less than the group median of non-CY-exposed residual T cells in the CD34 product (19.3% versus 58.1%; <em>P</em> = .009), without a concomitant increase in NRM. In its current form, this 2-step regimen was highly tolerable, but strategies to reduce relapse, potentially the addition of T cells not exposed to CY, are needed.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1861-1867"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38128914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression of Hematopoietic Primitive Cells in Patients with Secondary Failure of Platelet Recovery after Acute Graft-versus-Host Disease","authors":"Aijie Huang,&nbsp;Xiaoming Zhao,&nbsp;Meizhang Li,&nbsp;Gusheng Tang,&nbsp;Yang Fei,&nbsp;Roujia Wang,&nbsp;Lei Gao,&nbsp;Xiong Ni,&nbsp;Weiping Zhang,&nbsp;Jianmin Yang,&nbsp;Xiaoxia Hu,&nbsp;Jianmin Wang","doi":"10.1016/j.bbmt.2020.06.003","DOIUrl":"10.1016/j.bbmt.2020.06.003","url":null,"abstract":"<div><p>Secondary failure of platelet recovery (SFPR) can occur after allogeneic hematopoietic stem cell transplantation (alloHSCT), and 20% of cases are related to acute graft-versus-host disease (aGVHD). The underlying mechanisms of this association are unclear, however. The aim of the present study was to investigate the potential mechanisms of SFPR secondary to aGVHD, which may provide a new therapeutic strategy for these patients. A total of 468 patients with malignant hematologic disease who underwent alloHSCT were included. Sixty-six patients developed SFPR after alloHSCT, and in 45 of these 66 patients (68.2%), SFPR was secondary to grade II-IV aGVHD (SFPR/aGVHD). Compared with patients with good graft function (GGF), patients with SFPR had poor overall survival (20.72% versus 88.01%; <em>P &lt;</em> .0001). Grade II-IV aGVHD was identified as an independent risk factor for SFPR in multivariate analysis (hazard ratio, 9.512; <em>P &lt;</em> .0001). We observed reduced erythroid and megakaryocyte colony formation in bone marrow (BM) samples isolated from SFPR/aGVHD patients, consistent with the lower frequency of megakaryocyte and erythrocyte progenitors in BM. Levels of the inflammatory cytokines IL-2R and TNF-R1 were significantly higher in the SFPR/aGVHD group compared with the GGF group (<em>P</em> = .002 and .001, respectively), as were the frequencies of proinflammatory T helper subsets. Furthermore, the pathways that regulate hematopoiesis and immune responses were universally underexpressed in CD34⁺ cells isolated from SFPR/aGVHD patients. Differentially expressed genes were significantly enriched in the hematopoietic cell lineage pathway and other pathways involved in both immune responses and megakaryopoiesis. In summary, we found that both the immune microenvironment and compromised proliferation of hematopoietic primitive cells contribute to the development of SFPR secondary to aGVHD, and our data provide new insight into the mechanisms of SFPR in the context of aGVHD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1840-1854"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38045682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation","authors":"Nina Salooja ,&nbsp;Hildegaard Greinix ,&nbsp;Tapani Ruutu ,&nbsp;Steffie van der Werf ,&nbsp;Anja van Biezen ,&nbsp;Anita Lawitschka ,&nbsp;Grzegorz Basak ,&nbsp;Rafael Duarte","doi":"10.1016/j.bbmt.2020.06.022","DOIUrl":"10.1016/j.bbmt.2020.06.022","url":null,"abstract":"<div><p>Reduced bone mineral density (BMD) is a well-recognized complication of hematopoietic cell transplantation (HCT), with significant drops in BMD occurring within the first 12 months after HCT. Guidance on identifying and managing this complication is available in several published guidelines. In this study, we investigated current practices in the investigation and management of low BMD in centers registered with the European Society for Blood and Marrow Transplantation (EBMT). A questionnaire about bone health was sent to all registered centers, and responses were received from 99 centers in 25 countries (52%) currently registered with the EBMT. Our data highlight considerable heterogeneity in practices across European centers in relation to investigations, management, and use of guidelines. Our data demonstrate the need for better dissemination and implementation of existing guidelines and also for the development of multidisciplinary guidelines with input from all relevant stakeholders.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1955-1962"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1083879120303979/pdfft?md5=92314f167250d6ea920712c0b5fe8f40&pid=1-s2.0-S1083879120303979-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38123520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score","authors":"Mariano Berro ,&nbsp;Saurabh Chhabra ,&nbsp;José Luis Piñana ,&nbsp;Jorge Arbelbide ,&nbsp;Maria M. Rivas ,&nbsp;Ana Lisa Basquiera ,&nbsp;Adriana Vitriu ,&nbsp;Alejandro Requejo ,&nbsp;Vera Milovic ,&nbsp;Sebastian Yantorno ,&nbsp;Gonzalo Bentolila ,&nbsp;Juan Jose Garcia ,&nbsp;Martin Castro ,&nbsp;Silvina Palmer ,&nbsp;Martin Saslavsky ,&nbsp;Patricio Duarte ,&nbsp;Amalia Cerutti ,&nbsp;Gustavo Jarchum ,&nbsp;Matias Tisi Baña ,&nbsp;Bicky Thapa ,&nbsp;Gustavo Kusminsky","doi":"10.1016/j.bbmt.2020.06.028","DOIUrl":"10.1016/j.bbmt.2020.06.028","url":null,"abstract":"<div><p>There have been several efforts to predict mortality after autologous stem cell transplantation (ASCT), such as the hematopoietic cell transplant-comorbidity index (HCT-CI), described for allogeneic stem cell transplantation and validated for ASCT, but there is no composite score in the setting of ASCT combining comorbidities with other clinical characteristics. Our aim is to describe a comprehensive score combining comorbidities with other clinical factors and to analyze the impact of this score on nonrelapse mortality (NRM), overall survival (OS), and early morbidity endpoints (mechanical ventilation, shock or dialysis) after ASCT. For the training cohort, we retrospectively reviewed data of 2068 adult patients who received an ASCT in Argentina (October 2002 to June 2017) for multiple myeloma or lymphoma. For the validation cohort, we analyzed 2168 ASCTs performed in the Medical College of Wisconsin and Spanish stem cell transplant group (Grupo Español de Trasplante Hematopoyético (GETH)) (January 2012 to December 2018). We first performed a multivariate analysis for NRM in order to select and assign weight to the risk factors included in the score (male patients, aged 55 to 64 and ≥65 years, HCT-CI ≥3, Hodgkin lymphoma and non-Hodgkin lymphoma). The hazard ratio for NRM increased proportionally with the score. Patients were grouped as low risk (LR) with a score of 0 to 1 (686, 33%), intermediate risk (IR) with a score of 2 to 3 (1109, 53%), high risk (HR) with a score of 4 (198, 10%), and very high risk (VHR) with a score of ≥5 (75, 4%). The score was associated with a progressive increase in all the early morbidity endpoints. Moreover, the score was significantly associated with early NRM (day 100: 1.5% versus 2.4% versus 7.6% versus 17.6%) as well as long term (1 to 3 years; 1.8% to 2.3% versus 3.8% to 4.9% versus 11.7% to 14.5% versus 25.0% to 27.4%, respectively; <em>P</em>&lt; .0001) and OS (1 to 5 years; 94% to 73% versus 89% to 75% versus 76% to 47% versus 65% to 52% respectively; <em>P</em> &lt; .0001). The score was validated in an independent cohort (N = 2168) and was significantly associated with early and late events. In conclusion, we developed and validated a novel score predicting NRM and OS in 2 large cohorts of more than 2000 autologous transplant patients. This tool can be useful for tailoring conditioning regimens or defining risk for transplant program decision making.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1828-1832"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.06.028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38138135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Black Lives and Black Donors Matter Post-Hematopoietic Stem Cell Transplantation","authors":"Mitchell S. Cairo","doi":"10.1016/j.bbmt.2020.08.007","DOIUrl":"10.1016/j.bbmt.2020.08.007","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages e245-e246"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38255032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation","authors":"Saurabh Chhabra ,&nbsp;Alexis Visotcky ,&nbsp;Marcelo C. Pasquini ,&nbsp;Fenlu Zhu ,&nbsp;Xiaoying Tang ,&nbsp;Mei-Jie Zhang ,&nbsp;Robert Thompson ,&nbsp;Sameem Abedin ,&nbsp;Anita D'Souza ,&nbsp;Binod Dhakal ,&nbsp;William R. Drobyski ,&nbsp;Timothy S. Fenske ,&nbsp;James H. Jerkins ,&nbsp;J. Douglas Rizzo ,&nbsp;Lyndsey Runaas ,&nbsp;Wael Saber ,&nbsp;Nirav N. Shah ,&nbsp;Bronwen E. Shaw ,&nbsp;Mary M. Horowitz ,&nbsp;Parameswaran N. Hari ,&nbsp;Mehdi Hamadani","doi":"10.1016/j.bbmt.2020.07.005","DOIUrl":"10.1016/j.bbmt.2020.07.005","url":null,"abstract":"<div><p>Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor that has been shown in preclinical models to prevent GVHD. We conducted a phase I/II trial in 57 patients to evaluate the safety and efficacy of ixazomib administration for cGVHD prophylaxis in patients undergoing allogeneic HCT. Oral ixazomib was administered on a weekly basis for a total of 4 doses, beginning days +60 through +90, to recipients of matched related donor (MRD, n = 25) or matched unrelated donor (MUD, n = 26) allogeneic HCT in phase II portion of the study, once the recommended phase II dose of 4 mg was identified in phase I (n = 6). All patients received peripheral blood graft and standard GVHD prophylaxis of tacrolimus and methotrexate. Ixazomib administration was safe and well tolerated, with thrombocytopenia, leukopenia, gastrointestinal complaints, and fatigue the most common adverse events (&gt;10%). In phase II (n = 51), the cumulative incidence of cGVHD at 1 year was 36% (95% confidence interval [CI], 19% to 54%) in the MRD cohort and 39% (95% CI, 21% to 56%) in the MUD cohort. One-year cumulative incidence of nonrelapse mortality (NRM) and relapse was 0% and 20% (95% CI, 8% to 36%) in the MRD cohort, respectively. In the MUD cohort, the respective NRM and relapse rates were 4% (0% to 16%) and 34% (17% to 52%). The outcomes on the study were compared post hoc with contemporaneous matched Center for International Blood and Marrow Transplant Research (CIBMTR) controls. This post hoc analysis showed no significant improvement in cGVHD rates in both the MRD (hazard ratio [HR] = 0.85, <em>P</em> = .64) or MUD cohorts (HR = 0.68, <em>P</em> = .26) on the study compared with CIBMTR controls. B cell activating factor plasma levels were significantly higher after ixazomib dosing in those who remained cGVHD free compared with those developed cGVHD. This study shows that the novel strategy of short-course oral ixazomib following allogeneic HCT is safe but did not demonstrate significant improvement in cGVHD incidence in recipients of MRD and MUD transplantation compared with matched CIBMTR controls. This study is registered at <span>www.clinicaltrials.gov</span><svg><path></path></svg> as NCT02250300.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1876-1885"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38143804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}